

June 17, 2026

| | |
|--|---|
| To, National Stock Exchange of India Limited, "Exchange Plaza", 5th Floor, Plot No. C/1, G Block, Bandra- Kurla Complex Bandra (East), Mumbai – 400 051 | To, BSE Limited, Corporate Relationship Department, 2nd Floor, New Trading Ring, P.J. Towers, Dalal Street, Mumbai – 400 001 |
| Scrip Name: GLENMARK | Scrip Code: 532296 |
| ISIN: INE935A01035 | ISIN: INE935A01035 |
| Our Reference No. 23/26-27 | Our Reference No. 23/26-27 |

Dear Sir/ Madam,

Sub: Glenmark Pharmaceuticals Inc., USA launches Methylene Blue Injection USP, 50 mg/10 mL (5 mg/mL) Single-Dose Vial

Glenmark Pharmaceuticals Inc., USA (Glenmark) today announced the launch of Methylene Blue Injection USP, 50 mg/10 mL (5 mg/mL) Single-Dose Vial. Glenmark's Methylene Blue Injection USP is bioequivalent and therapeutically equivalent to the reference listed drug, ProvayBlue® Injection, 50 mg/10 mL (5 mg/mL), of Provepharm SAS [NDA 204630].

According to IQVIA® sales data for the 12-month period ending April 2026, the ProvayBlue® Injection, 50 mg/10 mL (5 mg/mL) market achieved annual sales of approximately \$19.0 million.

Kindly find attached media release which is self- explanatory.

Request you to kindly take the same on record.

Thanking You.

Yours faithfully,
For Glenmark Pharmaceuticals Limited

Rashmi Khandelwal
Company Secretary & Compliance Officer
ACS - 28839

Encl: As above

Glenmark Pharmaceuticals Limited

Glenmark House, B D Sawant Marg, Andheri (E), Mumbai 400 099

T: 91 22 4018 9999 F: 91 22 4018 9988 CIN No: L24299MH1977PLC019982 W: www.glenmarkpharma.com

Registered office: B/2, Mahalaxmi Chambers, 22 Bhulabhai Desai Road, Mumbai 400 026 E: complianceofficer@glenmarkpharma.com

Glenmark Pharmaceuticals Inc., USA launches Methylene Blue Injection USP, 50 mg/10 mL (5 mg/mL) Single-Dose Vial

Elmwood Park, New Jersey, June 17, 2026 – Glenmark Pharmaceuticals Inc., USA (Glenmark) today announced the launch¹ of Methylene Blue Injection USP, 50 mg/10 mL (5 mg/mL) Single-Dose Vial. Glenmark’s Methylene Blue Injection USP is bioequivalent and therapeutically equivalent to the reference listed drug, ProvayBlue^{®2} Injection, 50 mg/10 mL (5 mg/mL), of Provepharm SAS [NDA 204630].

According to IQVIA[®] sales data for the 12-month period ending April 2026, the ProvayBlue[®] Injection, 50 mg/10 mL (5 mg/mL) market³ achieved annual sales of approximately \$19.0 million*.

Commenting on the launch, Marc Kikuchi, President & Business Head, North America said, “The launch of Methylene Blue Injection USP reflects Glenmark’s ongoing commitment to expanding access to quality, affordable medicines for healthcare institutions and the patients they serve. This addition further strengthens our institutional portfolio and reinforces our focus on delivering reliable treatment options across the U.S. market.”

¹Glenmark’s Methylene Blue Injection USP, 50 mg/10 mL (5 mg/mL) Single-Dose Vial is only approved for the indication(s) listed in Glenmark’s approved label.

²All brand names and trademarks are the property of their respective owners.

³Market includes brand and all available therapeutic equivalents. Note: IQVIA[®] data obtained by Glenmark is only available for all approved RLD indications. Glenmark’s product is only approved for and will only be marketed for the indications listed in Glenmark’s approved label, which may be different than the approved RLD indications.

*IQVIA[®] National Sales Perspectives: Retail & Non-Retail, April 2026

About Glenmark Pharmaceuticals Limited:

Glenmark Pharmaceuticals Ltd. (BSE: 532296 | NSE: GLENMARK) is a global, research-led pharmaceutical company with a unique focus on innovation and accessibility. We pioneer transformative breakthrough therapies that aim to redefine treatment while expanding access to high-quality and affordable medicines for patients around the world. With 11 world-class manufacturing facilities across four continents, supported by six cutting-edge R&D centres, and a commercial footprint in 80+ countries, we deliver a diversified portfolio across branded, innovative, generics, and consumer health products, with a focus on respiratory, dermatology, and oncology. Scrip 100 positions Glenmark among the Top 100 biopharmaceutical companies globally by pharmaceutical sales for 2024. For more information, visit www.glenmarkpharma.com.

For more information, please contact:

| India | United States |
|--|--|
| <p>Akhila Natarajan mediarelations@glenmarkpharma.com +91 22 4018 9999</p> <p>Adfactors PR glenmark.ihcp@adfactorspr.com</p> | <p>Akhila Natarajan mediarelations@glenmarkpharma.com</p> <p>Danielle Hagen danielle@nahigianstrategies.com 202-365-6112</p> |